• Publications
  • Influence
Updated Data on Proximal Femur Bone Mineral Levels of US Adults
Abstract: This paper describes data on bone mineral levels in the proximal femur of US adults based on the nationally representative sample examined during both phases of the third National HealthExpand
  • 944
  • 79
Risk of new vertebral fracture in the year following a fracture.
CONTEXT Vertebral fractures significantly increase lifetime risk of future fractures, but risk of further vertebral fractures in the period immediately following a vertebral fracture has not beenExpand
  • 1,563
  • 63
  • PDF
Anabolic actions of parathyroid hormone on bone.
I. Introduction PHYSICIANS have traditionally considered PTH to be an agent that is catabolic to the skeleton. However, as early as 60 yr ago, Albright and his colleagues (1) and later Selye (2)Expand
  • 673
  • 44
Effects of Daily Treatment with Parathyroid Hormone on Bone Microarchitecture and Turnover in Patients with Osteoporosis: A Paired Biopsy Study *
We examined paired iliac crest bone biopsy specimens from patients with osteoporosis before and after treatment with daily injections of 400 U of recombinant, human parathyroid hormone 1–34Expand
  • 580
  • 44
Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers.
Osteoporosis in men poses a unique therapeutic challenge. Clinical studies have focused largely on the more prevalent problem of post-menopausal osteoporosis, with few gender-specific studiesExpand
  • 370
  • 22
Parathyroid Hormone Added to Established Hormone Therapy: Effects on Vertebral Fracture and Maintenance of Bone Mass After Parathyroid Hormone Withdrawal
Our best pharmacologic agents for osteoporosis treatment prevent no more than 40‐60% of osteoporotic fractures in patients at highest risk. Thus, there is a need for agents that can further augmentExpand
  • 294
  • 20
Effect of Recombinant Human Parathyroid Hormone (1-84) on Vertebral Fracture and Bone Mineral Density in Postmenopausal Women with Osteoporosis
Context Researchers have not previously reported the efficacy and safety of parathyroid hormone (1-84) (PTH) for the primary prevention of osteoporotic fractures. Contributions Among 2532Expand
  • 318
  • 19
Daily and cyclic parathyroid hormone in women receiving alendronate.
BACKGROUND We evaluated whether patients with osteoporosis treated with long-term alendronate have a response to parathyroid hormone treatment and whether short, three-month cycles of parathyroidExpand
  • 222
  • 19
  • PDF
Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis.
BACKGROUND Teriparatide (recombinant human parathyroid hormone [1-34]) reduces fracture risk in postmenopausal women with osteoporosis. We assessed the safety and incidence of new vertebral fracturesExpand
  • 261
  • 19
  • PDF
Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy
Teriparatide (rhPTH[1-34]), a bone-forming agent for the treatment of osteoporosis, increases bone mineral density in men and women, and reduces the risk of fractures in women with osteoporosis.Expand
  • 258
  • 19
  • PDF